Government News
Letters Outline Adverse Events
Psychiatric News
Volume 40 Number 8 page 66-66

A letter from Eli Lilly and Co. dated September 28, 2004, to European clinicians stated that a total of 49 adverse events, including eight fatal events, had been reported for Zyprexa IM as of August 31, 2004. Cardiorespiratory depression, hypotension, and bradycardia were among these reported cases.

The letter stated, "A review of the reported fatalities indicates use of Zyprexa IM in a manner that is inconsistent with the Summary of Product Characteristics including excessive dosing and/or inappropriate use of concomitant benzodiazepines and/or other antipsychotics."

The letter outlines the following recommendations about use of Zyprexa IM:

A similar letter to Canadian clinicians dated September 7, 2004, outlined the following examples of inappropriate use of Zyprexa IM that were reported to Lilly:

Interactive Graphics


Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Articles